Stay ahead of developments in federal and state health care law, regulation and transactions with timely, expert news and analysis.
June 23 — The House's 21st Century Cures legislation (H.R. 6) will cost $106.4 billion over five years ending 2020, according to a Congressional Budget Office estimate released June 23.
However, the CBO estimate takes into account the entire budget for the National Institutes of Health through 2019, which makes it difficult to estimate the actual costs and savings of the bill's provisions. The legislation, which unanimously passed the Energy and Commerce Committee in May, reauthorized appropriations for the NIH for three years. The CBO estimated that reauthorization would cost $97.1 billion.
The CBO also estimated an offset that would delay reinsurance payments to Medicare Part D drug plans would shift spending between fiscal years and would shift about $5 billion from fiscal 2025 to 2026. Under the legislation, the delay is supposed to generate $2 billion over 10 years by allowing the government to earn interest on the cash for a longer period of time. However, a committee aide told Bloomberg BNA June 23 that this offset won't be included when the bill—which seeks to spur development of new drugs and devices—makes it to the House floor for a vote, which could be shortly after the July 4 recess.
According to the Democratic aide, the final language will likely include multiple smaller offsets to cover the savings, instead of one large replacement policy.
The bill would authorize funding and modify programs within the HHS that support medical research, oversee the development and marketing approval for drugs and monitor the use of drugs in the U.S. The legislation also would change the regulatory framework surrounding medical devices and oversight of technology by the Food and Drug Administration.
According to the CBO, the amount authorized for the NIH by the legislation may not be what is appropriated. However, the legislation does require $2 billion in mandatory NIH funding annually over the next five years.
The aide said the committee is “quite close” to a floor vote, despite not meeting Rep. Fred Upton's (R-Mich.) self-imposed June deadline.
“If we come right back in July, if we lose a week, it's not make or break,” the aide said.
The bill contains numerous provisions that also fall under the jurisdiction of the Ways and Means Committee—such as Medicare coverage determinations, telemedicine, interoperability, site of service payments— but a staff member on that committee told Bloomberg BNA they still haven't been given a copy of the bill, which is something that should happen under normal legislative order. Both Democrats and Republicans have concerns over the language in those provisions, the staffer said.
The Energy and Commerce Committee doesn't need the approval of Ways and Means to bring the bill to the House floor, but “it's in their best interest” to do so, the Ways and Means staffer said.
The legislation also contains provisions that would grant an additional six months of exclusivity for certain brand-name drugs previously approved under the Federal Food, Drug, and Cosmetic Act (FDCA) if the drug is approved for a new indication that treats a rare disease or condition. According to the CBO, those extensions could delay the timing of market entry by lower-priced generic drugs or biosimilars.
The CBO estimated that about 15 percent of the share of brand-name sales for drugs previously approved under the FDCA that are expected to first experience generic competition before 2025 would have such competition delayed by six months under this provision.
The CBO estimated that the provision would increase on-budget spending on prescription drugs by mandatory health programs by $869 million over the 2016-2025 period. Beyond 2025, the potential for the legislation to delay the entry of generic drugs or biosimilars is greater, and the federal budgetary effect would increase in later years, the CBO said.
To contact the reporter on this story: Nathaniel Weixel in Washington at firstname.lastname@example.org
To contact the editor responsible for this story: Janey Cohen at email@example.com
All Bloomberg BNA treatises are available on standing order, which ensures you will always receive the most current edition of the book or supplement of the title you have ordered from Bloomberg BNA’s book division. As soon as a new supplement or edition is published (usually annually) for a title you’ve previously purchased and requested to be placed on standing order, we’ll ship it to you to review for 30 days without any obligation. During this period, you can either (a) honor the invoice and receive a 5% discount (in addition to any other discounts you may qualify for) off the then-current price of the update, plus shipping and handling or (b) return the book(s), in which case, your invoice will be cancelled upon receipt of the book(s). Call us for a prepaid UPS label for your return. It’s as simple and easy as that. Most importantly, standing orders mean you will never have to worry about the timeliness of the information you’re relying on. And, you may discontinue standing orders at any time by contacting us at 1.800.960.1220 or by sending an email to firstname.lastname@example.org.
Put me on standing order at a 5% discount off list price of all future updates, in addition to any other discounts I may quality for. (Returnable within 30 days.)
Notify me when updates are available (No standing order will be created).
This Bloomberg BNA report is available on standing order, which ensures you will all receive the latest edition. This report is updated annually and we will send you the latest edition once it has been published. By signing up for standing order you will never have to worry about the timeliness of the information you need. And, you may discontinue standing orders at any time by contacting us at 1.800.372.1033, option 5, or by sending us an email to email@example.com.
Put me on standing order
Notify me when new releases are available (no standing order will be created)